Alexander Bishop

Prof. Alexander Bishop

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2018 in Nature
Verified
Journal Article
Closed access
PDF file
AGAparna Gorthi
Aparna Gorthi
JRJuly Carolina Romero
July Carolina Romero
ELEva Loranc
Eva Loranc
LCLin Cao
Lin Cao
LLLiesl A. Lawrence
Liesl A. Lawrence
ABAlexander Bishop
Alexander Bishop

15 July 2020 in Nature
Verified
Journal Article
Closed access
PDF file
KAKaran J. Abraham
Karan J. Abraham
NKNegin Khosraviani
Negin Khosraviani
JCJanet N. Y. Chan
Janet N. Y. Chan
AGAparna Gorthi
Aparna Gorthi
ASAnas Samman
Anas Samman
KMKarim Mekhail
Karim Mekhail

1 April 2003 in Experimental and Molecular Pathology
Verified
Journal Article
Closed access
ABAlexander Bishop
Alexander Bishop
RSRobert H Schiestl
Robert H Schiestl

1 October 2000 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
ABAlexander Bishop
Alexander Bishop
RSRobert H. Schiestl
Robert H. Schiestl
Novel findings over the last 2 years have led to an increased emphasis on homologous recombination (HR) as both a pathway for DNA repair and a cause for genomic rearrangements. Indeed, environmental carcinogens increase the frequency of HR, as can be observed when two copies of a duplicated sequence recombine to delete the intervening sequences. Such HR events between dispersed homologous sequences may result in not only deletions, but also gene duplications or translocations. These types of genomic rearrangement have been observed to be the cause of several different genetic diseases, including cancer. In reflection of this, several genes have been identified that, when mutant, predispose an individual to an increased frequency of cancer. These genes have been shown to be either directly or indirectly involved in HR. In addition, HR is induced by a wide variety of carcinogens, preferentially in proliferating cells. This fits the most current models of recombination and its involvement in reinitiating stalled replication forks. Thus, ‘correct’ HR repair may act with high fidelity, an important issue for proliferating cells, but in the context of alternative homologous partner sequences, ‘aberrant’ HR can cause genomic rearrangements with dire consequences.

1 December 2016 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
Alfeu Zanotto-FilhoAlfeu Zanotto-Filho
Alfeu Zanotto-Filho
VMV. Pragathi Masamsetti
V. Pragathi Masamsetti
ELEva Loranc
Eva Loranc
STSonal S. Tonapi
Sonal S. Tonapi
AGAparna Gorthi
Aparna Gorthi
ABAlexander Bishop
Alexander Bishop
Alkylating agents are a commonly used cytotoxic class of anticancer drugs. Understanding the mechanisms whereby cells respond to these drugs is key to identify means to improve therapy while reducing toxicity. By integrating genome-wide gene expression profiling, protein analysis, and functional cell validation, we herein demonstrated a direct relationship between NRF2 and Endoplasmic Reticulum (ER) stress pathways in response to alkylating agents, which is coordinated by the availability of glutathione (GSH) pools. GSH is essential for both drug detoxification and protein thiol homeostasis within the ER, thus inhibiting ER stress induction and promoting survival, an effect independent of its antioxidant role. NRF2 accumulation induced by alkylating agents resulted in increased GSH synthesis via GCLC/GCLM enzyme, and interfering with this NRF2 response by either NRF2 knockdown or GCLC/GCLM inhibition with buthionine sulfoximine caused accumulation of damaged proteins within the ER, leading to PERK-dependent apoptosis. Conversely, upregulation of NRF2, through KEAP1 depletion or NRF2-myc overexpression, or increasing GSH levels with N-acetylcysteine or glutathione-ethyl-ester, decreased ER stress and abrogated alkylating agents–induced cell death. Based on these results, we identified a subset of lung and head-and-neck carcinomas with mutations in either KEAP1 or NRF2/NFE2L2 genes that correlate with NRF2 target overexpression and poor survival. In KEAP1-mutant cancer cells, NRF2 knockdown and GSH depletion increased cell sensitivity via ER stress induction in a mechanism specific to alkylating drugs. Overall, we show that the NRF2-GSH influence on ER homeostasis implicates defects in NRF2-GSH or ER stress machineries as affecting alkylating therapy toxicity. Mol Cancer Ther; 15(12); 3000–14. ©2016 AACR.

17 September 2022 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
DSDavid S. Shulman
David S. Shulman
SWSarah B. Whittle
Sarah B. Whittle
SDSurdez Didier
Surdez Didier
KBKelly M. Bailey
Kelly M. Bailey
ENRIQUE DE ALAVAENRIQUE DE ALAVA
ENRIQUE DE ALAVA
PGPatrick J. Grohar
Patrick J. Grohar
The advent of dose intensified interval compressed therapy has improved event-free survival for patients with localized Ewing sarcoma (EwS) to 78% at 5 years. However, nearly a quarter of patients with localized tumors and 60–80% of patients with metastatic tumors suffer relapse and die of disease. In addition, those who survive are often left with debilitating late effects. Clinical features aside from stage have proven inadequate to meaningfully classify patients for risk-stratified therapy. Therefore, there is a critical need to develop approaches to risk stratify patients with EwS based on molecular features. Over the past decade, new technology has enabled the study of multiple molecular biomarkers in EwS. Preliminary evidence requiring validation supports copy number changes, and loss of function mutations in tumor suppressor genes as biomarkers of outcome in EwS. Initial studies of circulating tumor DNA demonstrated that diagnostic ctDNA burden and ctDNA clearance during induction are also associated with outcome. In addition, fusion partner should be a pre-requisite for enrollment on EwS clinical trials, and the fusion type and structure require further study to determine prognostic impact. These emerging biomarkers represent a new horizon in our understanding of disease risk and will enable future efforts to develop risk-adapted treatment.